Literature DB >> 12839102

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology.

Mary C Zanarini1, Anna A Vujanovic, Elizabeth A Parachini, Jennifer L Boulanger, Frances R Frankenburg, John Hennen.   

Abstract

The purpose of this study was to assess the psychometric properties of the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD), the first clinician-administered scale for the assessment of change in DSM-IV borderline psychopathology. The questions for the measure were adapted from the BPD module of the Diagnostic Interview for DSM-IV Personality Disorders (DIPD-IV) to reflect a 1-week time frame and each of the nine criteria for BPD is rated on a five-point anchored rating scale of 0 to 4, yielding a total score of 0 to 36. Two diagnostic interviews that assess the presence of BPD were administered to 200 nonpsychotic patients: the BPD module of the DIPD-IV and the Revised Diagnostic Interview for Borderlines (DIB-R). The ZAN-BPD was also administered, blind to diagnostic information. In addition, each patient filled out a self-report measure of general psychopathology that is often used in borderline treatment studies, the Symptom Checklist 90 (SCL-90). The convergent validity of the ZAN-BPD and relevant scales of the SCL-90 and the DIB-R was assessed and found to be highly significant. The discriminant validity of the various scores of the ZAN-BPD was also found to be highly significant, easily discriminating the 139 patients who met the DSM-IV criteria for BPD from the 61 patients who did not. In addition, internal consistency of the ZAN-BPD was found to be high (Cronbach's alpha=0.85). The interrater reliability of the ZAN-BPD was assessed using 32 conjoint interviews, while same day test-retest reliability was assessed in a separate sample of 40 patients. All reliability raters were blind to all previously collected information concerning each subject. All intraclass correlations were in the good to excellent range. Finally, the sensitivity of the ZAN-BPD to change was assessed using a third sample of 41 patients who were reinterviewed by a blind rater 7 to 10 days after the ZAN-BPD was first administered. The SCL-90 was also readministered at this time. The correlations between difference scores of the ZAN-BPD and difference scores of the SCL-90 were found to be significant, indicating that the ZAN-BPD measures change in a clinically meaningful manner. Taken together, the results of this study suggest that the ZAN-BPD is a promising clinician-administered scale for the assessment of change in borderline psychopathology over time.

Entities:  

Mesh:

Year:  2003        PMID: 12839102     DOI: 10.1521/pedi.17.3.233.22147

Source DB:  PubMed          Journal:  J Pers Disord        ISSN: 0885-579X


  90 in total

Review 1.  Update on pharmacotherapy of borderline personality disorder.

Authors:  Mary C Zanarini
Journal:  Curr Psychiatry Rep       Date:  2004-02       Impact factor: 5.285

Review 2.  State of the art in the pharmacologic treatment of borderline personality disorder.

Authors:  Louis Feurino; Kenneth R Silk
Journal:  Curr Psychiatry Rep       Date:  2011-02       Impact factor: 5.285

3.  Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up.

Authors:  Nancee Blum; Don St John; Bruce Pfohl; Scott Stuart; Brett McCormick; Jeff Allen; Stephan Arndt; Donald W Black
Journal:  Am J Psychiatry       Date:  2008-02-15       Impact factor: 18.112

4.  Development of the self-report version of the Zanarini Rating Scale for Borderline Personality Disorder.

Authors:  Mary C Zanarini; Jolie L Weingeroff; Frances R Frankenburg; Garrett M Fitzmaurice
Journal:  Personal Ment Health       Date:  2015-07-14

5.  Remnants and changes in facial emotion processing in women with remitted borderline personality disorder: an EEG study.

Authors:  Isabella Schneider; Katja Bertsch; Natalie A Izurieta Hidalgo; Laura E Müller; Christian Schmahl; Sabine C Herpertz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-09-27       Impact factor: 5.270

6.  Randomized Controlled Trial of Web-Based Psychoeducation for Women With Borderline Personality Disorder.

Authors:  Mary C Zanarini; Lindsey C Conkey; Christina M Temes; Garrett M Fitzmaurice
Journal:  J Clin Psychiatry       Date:  2018 May/Jun       Impact factor: 4.384

Review 7.  Pharmacotherapy for borderline personality disorder--current evidence and recent trends.

Authors:  Jutta M Stoffers; Klaus Lieb
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

8.  Predictors of treatment response to an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder.

Authors:  Kim L Gratz; Katherine L Dixon-Gordon; Matthew T Tull
Journal:  Personal Disord       Date:  2014-01

9.  Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial.

Authors:  Jayashri Kulkarni; Natalie Thomas; Abdul-Rahman Hudaib; Emorfia Gavrilidis; Jasmin Grigg; Raelene Tan; Jacinta Cheng; Amelia Arnold; Caroline Gurvich
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

10.  Predictors of response to Systems Training for Emotional Predictability and Problem Solving (STEPPS) for borderline personality disorder: an exploratory study.

Authors:  D W Black; J Allen; D St John; B Pfohl; B McCormick; N Blum
Journal:  Acta Psychiatr Scand       Date:  2009-01-12       Impact factor: 6.392

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.